Th e estrogen receptor α (ER) protein is present in over two-thirds of breast cancers, where it functions in the nucleus as a ligand-dependent transcription factor to drive cell proliferation, survival, and invasiveness. Endocrine therapies to block ER activity are the most important systemic treatments for ER-positive breast cancers, though resistance is prevalent [1]. We need to understand the molecular determinants regulating ER DNA binding and activity to elucidate the mechanisms underlying this resistance.
Background
Th e estrogen receptor α (ER) protein is present in over two-thirds of breast cancers, where it functions in the nucleus as a ligand-dependent transcription factor to drive cell proliferation, survival, and invasiveness. Endocrine therapies to block ER activity are the most important systemic treatments for ER-positive breast cancers, though resistance is prevalent [1] . We need to understand the molecular determinants regulating ER DNA binding and activity to elucidate the mechanisms underlying this resistance.
Th e advancement of chromatin immunoprecipitation (ChIP)-based technologies, which combine ChIP with microarrays or high throughput sequencing (ChIP-seq), has helped to identify a network of co-regulators and their genome-wide DNA binding sites (known as their cistrome) that cooperate to regulate ER DNA binding and transcriptional activity. Th ese technologies have revealed that, in breast cancer cells, ER mostly binds to distal enhancers that are also enriched for Forkhead motifs [2] [3] [4] . Furthermore, the Forkhead protein FOXA1, a favorable prognostic factor that correlates with the luminal A breast cancer subtype and hormonal sensitivity [5] , has been shown to act as a pioneer factor, opening chromatin regions for the recruitment of ER to these DNA binding sites [6] . However, how global the importance of FOXA1 is in mediating ER function in breast cancer, as well as in other target tissues and under diff erent ligand conditions, and what are the underlying factors that determine FOXA1 specifi city remain open questions.
The article
To more broadly investigate the genome-wide relationship of ER and FOXA1 DNA-binding sites, Hurtado and colleagues [7] fi rst performed ChIP-seq of ER and FOXA1 in three diff erent breast cancer cell lines. FOXA1 binding events were found to be dynamic and cell-linespecifi c, a phenomenon potentially related to the insulator protein CTCF. Within each cell line, a signifi cant overlap of over 50% was found between ER and FOXA1 sites. FOXA1 was also found to mediate ER function in non-breast cancer cells and to act upstream of ERchromatin interactions, enabling ER binding at more con densed chromatin regions. Additionally, FOXA1 was required to globally facilitate ER-mediated transcription, since downregulation of FOXA1 aff ected the transcription of more than 95% of estrogen-regulated genes. Finally, FOXA1 knockdown resulted in signifi cant growth inhibition of MCF7 cells, substantiating the key role of FOXA1 in the estrogen response of breast cancer cells.
To study the ER cistromic profi le and the role of FOXA1 in mediating tamoxifen inhibition, estrogendeprived MCF-7 cells treated with estrogen or tamoxifen were subjected to ER ChIP-seq and gene expression micro array analyses. In contrast to a previous report [8] ,
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